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auDIence 
Surgeons, Operating Room Supervisors, Peri­
operative Nurses, Hospital Administrators, 
Hospital Risk Managers, Occupational Health 
& Safety Managers, Infection Preventionists, 
Surgeon Educators, Surgical Residents, Medi­
cal School Administrators/Faculty, and other 
Personnel 
MeDIcal specIaltIes 
General Surgery, Urology, Obstetrics/Gyne­
cology, Orthopedics, Anesthesiology, Surgical 
Technology, and any specialty that includes 
surgery of the muscle or fascia 
purpose 
The Food and Drug Administration (FDA), 
the Centers for Disease Control and Preven­
tion’s (CDC) National Institute for Occupa­
tional Safety and Health (NIOSH), and the 
Occupational Safety and Health Administra­
tion (OSHA) strongly encourage health care 
professionals to use blunt-tip suture needles as 
an alternative to standard suture needles when 
suturing fascia and muscle to decrease the risk 
of needlestick injury. 
Blunt-tIp suture neeDles 
Blunt-tip suture needles (Figure 1), which are 
not as sharp as standard (sharp-tip) suture nee­
dles, are designed to penetrate muscle and fas­
cia and reduce the risk of needlesticks. Blunt-
tip suture needles are regulated by the FDA and 
have been marketed in the U.S. for more than 
25 years. 
Figure 1: Blunt-tip Suture Needle 













suMMary oF proBleM anD scope 
Needlestick injuries continue to occur in surgical
settings when suturing muscle and fascia, despite
the availability of safety-engineered devices, such
as blunt-tip suture needles, and the endorsement
of their use by professional organizations. 
Needlestick injuries have the potential to expose 
health care personnel to bloodborne viruses, 
such as Hepatitis B Virus (HBV), Hepatitis C 
Virus (HCV), and Human Immunodeficiency 
Virus (HIV). Of the estimated 384,000 needle-
stick injuries occurring in hospitals each year, 
23 percent occur in surgical settings.1 Published 
literature indicates that while needlestick injury 
rates have been decreasing among non-surgical 
health care providers, this has not been the case 
among those who work in surgical settings. Ac­
cording to a 2010 article published in the As­
sociation of periOperative Registered Nurses 
Journal, more than half of needlestick injuries 
involving suture needles occur during the sutur­
ing of fascia or muscle. 2 
BeneFIts oF usIng Blunt-tIp
suture neeDles 
Published studies show that using blunt-tip 
suture needles reduces the risk of needlestick 
injuries from suture needles by 69 percent.3 Al­
though blunt-tip suture needles currently cost 
some 70 cents more than their standard suture 
needle counterparts, the benefits of reducing 
the risk of serious and potentially fatal blood-
borne infections for health care personnel sup­
port their use when clinically appropriate. 
A 2007 report suggests that the slight difference 
in costs of blunt- and sharp-tip suture needles 
is balanced by the economic savings associated 
with needlestick injury prevention. This re­
port, which assessed the costs of managing oc­
cupational exposures to blood and body fluids, 
concluded that the cost of managing a needle-
stick injury can range from $376 to $2,456 per 
reported incident.4 In addition, personnel who 
receive needlestick injuries may experience anx­
iety and a loss of productivity as they await the 
results of blood tests. 
governMent agencIes anD proFessIonal 
organIzatIons enDorse tHe use oF Blunt­
tIp suture neeDles 
The OSHA Bloodborne Pathogen standard, 
revised on Jan.18, 2001 in response to the 
Needlestick Safety and Prevention Act of 2000, 
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4	 O’Malley EM, Scott RD 2nd, Gayle J, et al. Costs of management of occupational exposures to blood and body fluids. 
Infection Control Hospital Epidemiology. 2007; 28(7):774-82. 
3	 Parantainen A, Verbeek JH, Lavoie MC, Pahwa M. Blunt versus sharp suture needles for preventing percutaneous 
exposure incidents in surgical staff. Cochrane Database of Systematic Reviews 2011;Issue 11. Art. No.: CD009170. DOI: 
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requires the use of safer devices, such as blunt-
tip suture needles, when clinically appropriate, 
to reduce the risk of needlestick injury and sub­
sequent pathogen transmission to personnel. 
The revised standard requires employers, with 
input from non-managerial direct patient care 
employees, to consider and implement available 
appropriate and effective safer medical devices 
designed to eliminate or minimize occupation­
al exposure. 
In 2007, OSHA and NIOSH issued a joint 
Safety and Health Information Bulletin em­
phasizing OSHA’s requirement and NIOSH’s 
recommendation to use blunt-tip suture nee­
dles, when clinically appropriate, to decrease 
needlestick injuries to surgical personnel. 
The American College of Surgeons (ACS)
recommends the universal adoption of blunt-
tip suture needles as the first choice for the
closure of fascia and muscle. This statement is
endorsed by the Association of periOperative
Registered Nurses, American Association of
Nurse Anesthetists, American Association of
Surgical Physician Assistants, American Soci­
ety of Anesthesiologists, American Society of
PeriAnesthesia Nurses, and Association of Sur­
gical Technologists. 
In addition, the 2011 Viral Hepatitis Action 
Plan issued by the U.S. Department of Health 
and Human Services recommends the use of 
blunt-tip suture needles, when clinically appro­
priate, to help reduce device-related needlestick 
exposures among health care personnel. 
recoMMenDatIon 
The FDA, NIOSH, and OSHA strongly en­
courage health care professionals in surgical
settings to use blunt-tip suture needles to su­
ture muscle and fascia, when clinically appro­
priate, to reduce the risk of needlestick injury




When an employee reports a sharps injury to 
their employer, the OSHA Bloodborne Patho­
gens standard requires the employer to record 
the injury, make immediately available to the 
employee a confidential medical evaluation 
and provide follow-up immediately available 
to the employee, and investigate and document 
the circumstances and type of device involved. 
The employer can use this information to as­
sist in preventing similar injuries in the future. 
Needlestick injuries must be documented as re­
quired in OSHA’s Recordkeeping standard (29 
CFR 1904.8). 
In addition, OSHA’s Bloodborne Pathogens
standard (29 CFR 1910.1030(h)(5)) states
that any employer required to keep occupa­
tional injuries and illnesses records under 29
CFR 1904 must maintain a sharps injury log to
record needlestick injuries. The sharps injury
log should contain, at a minimum, the follow­
ing information: 
•	 Type and brand of device involved in 
the incident; 










•	 Department or work area where the 
exposure incident occurred; and 
•	 Explanation of how the incident occurred. 
Furthermore, prompt reporting of adverse 
events can help the FDA identify and better 
understand the risks associated with medical 
devices. If you suspect a problem with suture 
needles (sharp and blunt), we encourage you 
to file a voluntary report through MedWatch, 
the FDA Safety Information and Adverse Event 
Reporting program. Health care personnel em­
ployed by facilities that are subject to FDA’s 
user facility reporting requirements should 
follow the reporting procedures established by 
their facilities. Additional information about 
types of needlestick adverse events to report to 
the FDA is available at Needlesticks – Medical 
Device Reporting Guidance for User Facilities, 
Manufacturers and Importers. 
To help the FDA learn as much as possible 
about the adverse events associated with suture 
needles, please include the following informa­
tion in your reports, if available: 
•	 Manufacturer’s name 
•	 Device name (needle brand name) 
•	 Type of needle (blunt or sharp) 
•	 Type of suture 
•	 Date device was manufactured 
•	 Distributor’s name 
•	 Details of adverse event and medical and/or 
surgical interventions (if required)
 
ƌ Date the event occurred
 
ƌ	 Location of the event 
ƌ	 Nature of the injury and associated 
health outcome 
ƌ Status of the device 
ƌ Can the FDA contact the reporter for 
further follow-up 
contact InForMatIon 
If you have questions about OSHA’s Blood-
borne Pathogens standard and its requirement 
to use safer devices to prevent needlestick in­
juries, contact OSHA’s Directorate of Techni­
cal Support and Emergency Management at 
1-800-321-6742 or 202-693-2300. 
If you have questions about this communication, 
please contact FDA’s Division of Small Manu­
facturers, International and Consumer Assis­
tance (DSMICA) at DSMICA@FDA.HHS. 
GOV, 1-800-638-2041, or 301-796-7100. 
aDDItIonal lInks 
1.	 Bloodborne Pathogens and Needlestick 
Prevention Safety and Health Topics Page 
2.	 Frequently Asked Questions about the 
Needlestick Safety and Prevention Act 
3.	 Use of Blunt-Tip Suture Needles to De­
crease Percutaneous Injuries to Surgical 
Personnel Safety and Health Information 
Bulletin  
4.	 Needlesticks — Medical Device Reporting 
Guidance for User Facilities, Manufactur­
ers and Importers 
